Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York (preprint)
medrxiv; 2020.
Preprint
en Inglés
| medRxiv | ID: ppzbmed-10.1101.2020.05.25.20113050
ABSTRACT
Importance New York State (NYS) is an epicenter of the United States' COVID-19 epidemic. Reliable estimates of cumulative incidence of SARS-CoV-2 infection in the population are critical to tracking the extent of transmission and informing policies, but US data are lacking, in part because societal closure complicates study conduct. Objective:
To estimate the cumulative incidence of SARS-CoV-2 infection and percent of infections diagnosed in New York State, overall and by region, age, sex, and race and ethnicity.Design:
Statewide cross-sectional seroprevalence study, conducted April 19-28, 2020.Setting:
Grocery stores (n=99) located in 26 counties throughout NYS, which were essential businesses that remained open during a period of societal closure and attract a heterogenous clientele.Participants:
Convenience sample of patrons >=18 years and residing in New York State, recruited consecutively upon entering stores and via an in-store flyer. Exposures Region (New York City, Westchester/Rockland, Long Island, Rest of New York State), age, sex, race and ethnicity. MainOutcomes:
Primaryoutcome:
cumulative incidence of SARS-CoV-2 infection, based on dry-blood spot (DBS) SARS-CoV-2 antibody reactivity; secondaryoutcome:
percent of infections diagnosed.Results:
Among 15,101 adults with suitable DBS specimens, 1,887 (12.5%) were reactive using a validated SARS-CoV-2 IgG microsphere immunoassay (sensitivity 87.9%, specificity 99.75%). Following post-stratification weighting on region, sex, age, and race and ethnicity and adjustment for assay characteristics, estimated cumulative incidence through March 29 was 14.0% (95% CI 13.3-14.7%), corresponding to 2,139,300 (95% CI 2,035,800-2,242,800) infection-experienced adults. Cumulative incidence was higher among Hispanic/Latino (29.2%, 95% CI 27.2-31.2%), non-Hispanic black/African American (20.2% 95% CI, 18.1-22.3%), and non-Hispanic Asian (12.4%, 95% CI 9.4-15.4%) adults than non-Hispanic white adults (8.1%, 95% CI 7.4-8.7%, p
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
medRxiv
Asunto principal:
COVID-19
Idioma:
Inglés
Año:
2020
Tipo del documento:
Preprint
Similares
MEDLINE
...
LILACS
LIS